Introduction
cancer, Cancer
CANCER, SOLID TUMORS, CANCER
Edited by: Xuesong Gu, Beth Israel Deaconess Medical Center and Harvard Medical School, United StatesReviewed by: Eda K. Holl, Duke University, United States; Shouju Wang, Nanjing Medical University, ChinaThis article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in ImmunologyCombination therapeutic mode is likely to be the key to enhance the efficacy of immunotherapy in a wider range of cancer patients. Herein, we conducted an open-label, single-arm, multicenter, phase II clinical trial that enrolled patients with advanced solid tumors who had progressed after standard treatments.